Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biktarvy Switch in Elderly HIV Patients
NCT05147740Phase 4Unknown
- Start
- Jul 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1). Primary endpoints: HIV Treatment Satisfaction Questionnaire (HIVTSQ) at 48 weeks and HIV-Dependent Quality of Life (HIVDQoL) at 48 weeks. Status: unknown.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05147740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147740.